New drug trial offers hope for blood disorder patients
NCT ID NCT07052006
Summary
This study is testing an experimental drug called HT-6184 for people with myelodysplastic syndrome (MDS) who have anemia that causes symptoms. The trial aims to see if the drug can improve blood counts and is safe for patients. Participants will receive treatment for 16 to 32 weeks while doctors monitor their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
All India Institute of Medical Sciences
Dehradun, Rishkesh, 249203, India
-
Apollo Cancer Centre
Hyderabad, Telangana, 500033, India
-
Dr. Bafna's Star Superspeciality Clinic and Hospital
Kolhāpur, Maharashtra, 416005, India
-
HCG Cancer Center Vizag
Visakhapatnam, Krishna, 530040, India
-
Hemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences
Ahmedabad, Gujarat, 380009, India
-
Malabar Cancer Center
Kannur, Kerala, 670103, India
-
Meenakshi Mission Hospital and Research Centre
Madurai, Tamil Nadu, 625107, India
-
Nil Ratan Sircar Medical College and Hospital
Kolkata, West Bengal, 700014, India
-
Shalby Hospital
Ahmedabad, Gujarat, 380015, India
-
Tata Medical Center
Kolkata, West Bengal, 700160, India
Conditions
Explore the condition pages connected to this study.